Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-03-18

AUTHORS

Meral Calguneri, Zeynep Ozbalkan, M. Akif Ozturk, Sule Apras, A. Ihsan Ertenli, Sedat Kiraz

ABSTRACT

The objective of this study is to evaluate the efficacy, toxicity, and long-term outcome of low-dose IV cyclophosphamid therapy with repeated frequent intervals in combination with oral and IV methylprednisolone in patients with SLE nephritis. In this study, 113 patients diagnosed as having SLE and glomerulonephritis were assessed in between 1993 and 2002, with a median follow-up of 44.1±41.2 months. The patients were treated with 500 mg IV cyclophosphamide and 1 g IV methylprednisolone together with 60 mg/alternate-day oral methylprednisolone in a given schedule. The clinical and laboratory data were evaluated. There were significant improvements in the clinical and the laboratory parameters. Six patients died shortly after being hospitalized due to the disease activity itself. Eight patients were excluded from the study because of low compliance. The renal functions of the patients remained stable throughout the therapy; only 16/99 patients needed one or two additional pulses. Temporary leukopenia developed in 18/99 patients and diminished with the suspension or prolongation of the IV cyclophosphamide administration. Gastrointestinal side effects, which needed extra medication, developed in 20 patients. Hematuria was observed in 6/99 patients. Menstrual abnormalities were seen in 7/99 patients. No serious infections due to immunosuppression were observed with the given regimen. Hypertension was observed in 13 patients (minimum of 140/90 mmHg, maximum of 190/110 mmHg) and controlled with angiotensine-converting enzyme inhibitors. Mild central obesity was observed in 15 of the patients. Leimyosarcoma was observed in one patient who died during the follow-up period. Therapy starting with the weekly low-dose IV cyclophosphamide to induce remission together with IV and oral steroids, followed by prolonged intervals with the same doses for 2 years, appears to be useful in preserving renal function without major side effects in patients with lupus nephritis, in comparison to other studies. More... »

PAGES

782-788

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-006-0217-2

DOI

http://dx.doi.org/10.1007/s10067-006-0217-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008195734

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16547692


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematuria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Longitudinal Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lupus Nephritis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Menstruation Disturbances", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methylprednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Obesity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calguneri", 
        "givenName": "Meral", 
        "id": "sg:person.01071137677.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071137677.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sehit Ismail Eres Sok. Sahinler Apt 4/9, 06570, Ankara, Maltepe, Turkey", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey", 
            "Sehit Ismail Eres Sok. Sahinler Apt 4/9, 06570, Ankara, Maltepe, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozbalkan", 
        "givenName": "Zeynep", 
        "id": "sg:person.01102254177.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102254177.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Section of Rheumatology, Gazi University School of Medicine, Ankara, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.25769.3f", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Gazi University School of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozturk", 
        "givenName": "M. Akif", 
        "id": "sg:person.011712636000.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712636000.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Apras", 
        "givenName": "Sule", 
        "id": "sg:person.01301012316.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301012316.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ertenli", 
        "givenName": "A. Ihsan", 
        "id": "sg:person.01106677040.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106677040.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kiraz", 
        "givenName": "Sedat", 
        "id": "sg:person.01171322744.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171322744.01"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-03-18", 
    "datePublishedReg": "2006-03-18", 
    "description": "The objective of this study is to evaluate the efficacy, toxicity, and long-term outcome of low-dose IV cyclophosphamid therapy with repeated frequent intervals in combination with oral and IV methylprednisolone in patients with SLE nephritis. In this study, 113 patients diagnosed as having SLE and glomerulonephritis were assessed in between 1993 and 2002, with a median follow-up of 44.1\u00b141.2\u00a0months. The patients were treated with 500\u00a0mg IV cyclophosphamide and 1\u00a0g IV methylprednisolone together with 60\u00a0mg/alternate-day oral methylprednisolone in a given schedule. The clinical and laboratory data were evaluated. There were significant improvements in the clinical and the laboratory parameters. Six patients died shortly after being hospitalized due to the disease activity itself. Eight patients were excluded from the study because of low compliance. The renal functions of the patients remained stable throughout the therapy; only 16/99 patients needed one or two additional pulses. Temporary leukopenia developed in 18/99 patients and diminished with the suspension or prolongation of the IV cyclophosphamide administration. Gastrointestinal side effects, which needed extra medication, developed in 20 patients. Hematuria was observed in 6/99 patients. Menstrual abnormalities were seen in 7/99 patients. No serious infections due to immunosuppression were observed with the given regimen. Hypertension was observed in 13 patients (minimum of 140/90\u00a0mmHg, maximum of 190/110\u00a0mmHg) and controlled with angiotensine-converting enzyme inhibitors. Mild central obesity was observed in 15 of the patients. Leimyosarcoma was observed in one patient who died during the follow-up period. Therapy starting with the weekly low-dose IV cyclophosphamide to induce remission together with IV and oral steroids, followed by prolonged intervals with the same doses for 2\u00a0years, appears to be useful in preserving renal function without major side effects in patients with lupus nephritis, in comparison to other studies.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-006-0217-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "lupus nephritis", 
      "renal function", 
      "side effects", 
      "low-dose intravenous cyclophosphamide", 
      "alternate-day steroid therapy", 
      "long-term outcomes", 
      "gastrointestinal side effects", 
      "major side effects", 
      "oral methylprednisolone", 
      "temporary leukopenia", 
      "oral steroids", 
      "intravenous cyclophosphamide", 
      "steroid therapy", 
      "disease activity", 
      "central obesity", 
      "SLE nephritis", 
      "laboratory parameters", 
      "menstrual abnormalities", 
      "cyclophosphamide administration", 
      "serious infections", 
      "extra medication", 
      "same doses", 
      "patients", 
      "enzyme inhibitors", 
      "low compliance", 
      "methylprednisolone", 
      "nephritis", 
      "therapy", 
      "cyclophosphamide", 
      "laboratory data", 
      "prolonged intervals", 
      "frequent intervals", 
      "significant improvement", 
      "leukopenia", 
      "hematuria", 
      "hypertension", 
      "remission", 
      "glomerulonephritis", 
      "immunosuppression", 
      "medications", 
      "regimen", 
      "leimyosarcoma", 
      "obesity", 
      "SLE", 
      "study", 
      "infection", 
      "steroids", 
      "abnormalities", 
      "doses", 
      "prolongation", 
      "administration", 
      "months", 
      "intervals", 
      "efficacy", 
      "outcomes", 
      "inhibitors", 
      "toxicity", 
      "effect", 
      "compliance", 
      "years", 
      "schedule", 
      "function", 
      "period", 
      "activity", 
      "improvement", 
      "objective", 
      "combination", 
      "additional pulses", 
      "data", 
      "comparison", 
      "suspension", 
      "parameters", 
      "pulses", 
      "dose IV cyclophosphamid therapy", 
      "IV cyclophosphamid therapy", 
      "cyclophosphamid therapy", 
      "alternate-day oral methylprednisolone", 
      "angiotensine-converting enzyme inhibitors", 
      "Mild central obesity", 
      "oral alternate-day steroid therapy"
    ], 
    "name": "Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)", 
    "pagination": "782-788", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008195734"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-006-0217-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16547692"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-006-0217-2", 
      "https://app.dimensions.ai/details/publication/pub.1008195734"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_416.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-006-0217-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-006-0217-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-006-0217-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-006-0217-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-006-0217-2'


 

This table displays all metadata directly associated to this object as RDF triples.

268 TRIPLES      21 PREDICATES      127 URIs      119 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-006-0217-2 schema:about N0fd5d4611c2d445f8e20072b0e62bd6c
2 N3a70fa3d2cd2404aa2d4527aa72c52ed
3 N43b1cf3055a94038b1f09f4c437d9afc
4 N4480e9347f7440689517145be375b206
5 N4906ea811e3f4c2a8e64e268a0428cb2
6 N4fac8c34493a4874a5b4116c34f95936
7 N4fd3f6466a6f43e992d580726bdff049
8 N57e299734e2143d79c027c232ecb6d1b
9 N62699dba464a496497e5cfa30c24429c
10 N7890b52464bb43808cbe5965de4fa701
11 N7d7f23353f724808bc8c0d2bb83d6a5a
12 N7da75315c86f401f805b4129d1fc87bf
13 N83643e3b5936486b9cbc64bd31407965
14 N98a8bd752cb9494d972d758392fc7350
15 Na94ddc045c9c4b448d7b022177432cd3
16 Nae0e647bc3fb4e509e22266eb4eb8ef5
17 Nb594df373dc4494cb7a1c717e43b5e79
18 Ncad2edae8aea456f8a3bc62499f1ac9d
19 Nd1c74fa785e74d7bbb18d24f299c48c3
20 Nf1064ff1c6944516a186af84334b99cd
21 Nf52d59fe9e6244a795a9e8db021b9ce0
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N11fe00eb3680470abc10442f2a9c441b
25 schema:datePublished 2006-03-18
26 schema:datePublishedReg 2006-03-18
27 schema:description The objective of this study is to evaluate the efficacy, toxicity, and long-term outcome of low-dose IV cyclophosphamid therapy with repeated frequent intervals in combination with oral and IV methylprednisolone in patients with SLE nephritis. In this study, 113 patients diagnosed as having SLE and glomerulonephritis were assessed in between 1993 and 2002, with a median follow-up of 44.1±41.2 months. The patients were treated with 500 mg IV cyclophosphamide and 1 g IV methylprednisolone together with 60 mg/alternate-day oral methylprednisolone in a given schedule. The clinical and laboratory data were evaluated. There were significant improvements in the clinical and the laboratory parameters. Six patients died shortly after being hospitalized due to the disease activity itself. Eight patients were excluded from the study because of low compliance. The renal functions of the patients remained stable throughout the therapy; only 16/99 patients needed one or two additional pulses. Temporary leukopenia developed in 18/99 patients and diminished with the suspension or prolongation of the IV cyclophosphamide administration. Gastrointestinal side effects, which needed extra medication, developed in 20 patients. Hematuria was observed in 6/99 patients. Menstrual abnormalities were seen in 7/99 patients. No serious infections due to immunosuppression were observed with the given regimen. Hypertension was observed in 13 patients (minimum of 140/90 mmHg, maximum of 190/110 mmHg) and controlled with angiotensine-converting enzyme inhibitors. Mild central obesity was observed in 15 of the patients. Leimyosarcoma was observed in one patient who died during the follow-up period. Therapy starting with the weekly low-dose IV cyclophosphamide to induce remission together with IV and oral steroids, followed by prolonged intervals with the same doses for 2 years, appears to be useful in preserving renal function without major side effects in patients with lupus nephritis, in comparison to other studies.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N71a321e5df434bcf87cec0a715102d48
32 N7ffdb22d15ce4b3db587e1153b35ad5a
33 sg:journal.1093299
34 schema:keywords IV cyclophosphamid therapy
35 Mild central obesity
36 SLE
37 SLE nephritis
38 abnormalities
39 activity
40 additional pulses
41 administration
42 alternate-day oral methylprednisolone
43 alternate-day steroid therapy
44 angiotensine-converting enzyme inhibitors
45 central obesity
46 combination
47 comparison
48 compliance
49 cyclophosphamid therapy
50 cyclophosphamide
51 cyclophosphamide administration
52 data
53 disease activity
54 dose IV cyclophosphamid therapy
55 doses
56 effect
57 efficacy
58 enzyme inhibitors
59 extra medication
60 frequent intervals
61 function
62 gastrointestinal side effects
63 glomerulonephritis
64 hematuria
65 hypertension
66 immunosuppression
67 improvement
68 infection
69 inhibitors
70 intervals
71 intravenous cyclophosphamide
72 laboratory data
73 laboratory parameters
74 leimyosarcoma
75 leukopenia
76 long-term outcomes
77 low compliance
78 low-dose intravenous cyclophosphamide
79 lupus nephritis
80 major side effects
81 medications
82 menstrual abnormalities
83 methylprednisolone
84 months
85 nephritis
86 obesity
87 objective
88 oral alternate-day steroid therapy
89 oral methylprednisolone
90 oral steroids
91 outcomes
92 parameters
93 patients
94 period
95 prolongation
96 prolonged intervals
97 pulses
98 regimen
99 remission
100 renal function
101 same doses
102 schedule
103 serious infections
104 side effects
105 significant improvement
106 steroid therapy
107 steroids
108 study
109 suspension
110 temporary leukopenia
111 therapy
112 toxicity
113 years
114 schema:name Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)
115 schema:pagination 782-788
116 schema:productId N2e631afa617049fbb034b4818a9f6bc9
117 N2efa91cc917244e89295d307c8534ab1
118 Nea735acc6de749a38edc525b9ec6d598
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008195734
120 https://doi.org/10.1007/s10067-006-0217-2
121 schema:sdDatePublished 2021-11-01T18:09
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N3266793756a64d4d97fedc01de2a01c9
124 schema:url https://doi.org/10.1007/s10067-006-0217-2
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N0a5ac54bce9c4b389d15163f4e35e805 rdf:first sg:person.01102254177.19
129 rdf:rest N91000e9af1f64cff93d235cb44ad5158
130 N0fd5d4611c2d445f8e20072b0e62bd6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Injections, Intravenous
132 rdf:type schema:DefinedTerm
133 N11fe00eb3680470abc10442f2a9c441b rdf:first sg:person.01071137677.71
134 rdf:rest N0a5ac54bce9c4b389d15163f4e35e805
135 N22bb6e4003ef4bb1a5484f2df534239a rdf:first sg:person.01106677040.12
136 rdf:rest N4134cb2c1daa471a880c286e46a2dd9f
137 N2e631afa617049fbb034b4818a9f6bc9 schema:name pubmed_id
138 schema:value 16547692
139 rdf:type schema:PropertyValue
140 N2efa91cc917244e89295d307c8534ab1 schema:name dimensions_id
141 schema:value pub.1008195734
142 rdf:type schema:PropertyValue
143 N3266793756a64d4d97fedc01de2a01c9 schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N3a70fa3d2cd2404aa2d4527aa72c52ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Male
147 rdf:type schema:DefinedTerm
148 N4134cb2c1daa471a880c286e46a2dd9f rdf:first sg:person.01171322744.01
149 rdf:rest rdf:nil
150 N43b1cf3055a94038b1f09f4c437d9afc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Menstruation Disturbances
152 rdf:type schema:DefinedTerm
153 N4480e9347f7440689517145be375b206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Female
155 rdf:type schema:DefinedTerm
156 N4906ea811e3f4c2a8e64e268a0428cb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Methylprednisolone
158 rdf:type schema:DefinedTerm
159 N4fac8c34493a4874a5b4116c34f95936 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Longitudinal Studies
161 rdf:type schema:DefinedTerm
162 N4fd3f6466a6f43e992d580726bdff049 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Dose-Response Relationship, Drug
164 rdf:type schema:DefinedTerm
165 N57e299734e2143d79c027c232ecb6d1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Gastrointestinal Diseases
167 rdf:type schema:DefinedTerm
168 N58b289f2b10b4aecac449408497576a5 rdf:first sg:person.01301012316.26
169 rdf:rest N22bb6e4003ef4bb1a5484f2df534239a
170 N62699dba464a496497e5cfa30c24429c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Immunosuppressive Agents
172 rdf:type schema:DefinedTerm
173 N71a321e5df434bcf87cec0a715102d48 schema:volumeNumber 25
174 rdf:type schema:PublicationVolume
175 N7890b52464bb43808cbe5965de4fa701 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Cyclophosphamide
177 rdf:type schema:DefinedTerm
178 N7d7f23353f724808bc8c0d2bb83d6a5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Hematuria
180 rdf:type schema:DefinedTerm
181 N7da75315c86f401f805b4129d1fc87bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Middle Aged
183 rdf:type schema:DefinedTerm
184 N7ffdb22d15ce4b3db587e1153b35ad5a schema:issueNumber 6
185 rdf:type schema:PublicationIssue
186 N83643e3b5936486b9cbc64bd31407965 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Administration, Oral
188 rdf:type schema:DefinedTerm
189 N91000e9af1f64cff93d235cb44ad5158 rdf:first sg:person.011712636000.38
190 rdf:rest N58b289f2b10b4aecac449408497576a5
191 N98a8bd752cb9494d972d758392fc7350 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Hypertension
193 rdf:type schema:DefinedTerm
194 Na94ddc045c9c4b448d7b022177432cd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Treatment Outcome
196 rdf:type schema:DefinedTerm
197 Nae0e647bc3fb4e509e22266eb4eb8ef5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Leukopenia
199 rdf:type schema:DefinedTerm
200 Nb594df373dc4494cb7a1c717e43b5e79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Adult
202 rdf:type schema:DefinedTerm
203 Ncad2edae8aea456f8a3bc62499f1ac9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Glucocorticoids
205 rdf:type schema:DefinedTerm
206 Nd1c74fa785e74d7bbb18d24f299c48c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Lupus Nephritis
208 rdf:type schema:DefinedTerm
209 Nea735acc6de749a38edc525b9ec6d598 schema:name doi
210 schema:value 10.1007/s10067-006-0217-2
211 rdf:type schema:PropertyValue
212 Nf1064ff1c6944516a186af84334b99cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Obesity
214 rdf:type schema:DefinedTerm
215 Nf52d59fe9e6244a795a9e8db021b9ce0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Humans
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
222 schema:name Clinical Sciences
223 rdf:type schema:DefinedTerm
224 sg:journal.1093299 schema:issn 0770-3198
225 1434-9949
226 schema:name Clinical Rheumatology
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01071137677.71 schema:affiliation grid-institutes:grid.14442.37
230 schema:familyName Calguneri
231 schema:givenName Meral
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071137677.71
233 rdf:type schema:Person
234 sg:person.01102254177.19 schema:affiliation grid-institutes:None
235 schema:familyName Ozbalkan
236 schema:givenName Zeynep
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102254177.19
238 rdf:type schema:Person
239 sg:person.01106677040.12 schema:affiliation grid-institutes:grid.14442.37
240 schema:familyName Ertenli
241 schema:givenName A. Ihsan
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106677040.12
243 rdf:type schema:Person
244 sg:person.011712636000.38 schema:affiliation grid-institutes:grid.25769.3f
245 schema:familyName Ozturk
246 schema:givenName M. Akif
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712636000.38
248 rdf:type schema:Person
249 sg:person.01171322744.01 schema:affiliation grid-institutes:grid.14442.37
250 schema:familyName Kiraz
251 schema:givenName Sedat
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171322744.01
253 rdf:type schema:Person
254 sg:person.01301012316.26 schema:affiliation grid-institutes:grid.14442.37
255 schema:familyName Apras
256 schema:givenName Sule
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301012316.26
258 rdf:type schema:Person
259 grid-institutes:None schema:alternateName Sehit Ismail Eres Sok. Sahinler Apt 4/9, 06570, Ankara, Maltepe, Turkey
260 schema:name Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey
261 Sehit Ismail Eres Sok. Sahinler Apt 4/9, 06570, Ankara, Maltepe, Turkey
262 rdf:type schema:Organization
263 grid-institutes:grid.14442.37 schema:alternateName Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey
264 schema:name Department of Internal Medicine, Section of Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey
265 rdf:type schema:Organization
266 grid-institutes:grid.25769.3f schema:alternateName Department of Internal Medicine, Section of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
267 schema:name Department of Internal Medicine, Section of Rheumatology, Gazi University School of Medicine, Ankara, Turkey
268 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...